Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Start-up Funding Crowdfunding Investment Venture Capital Entrepreneurship Internet Business Technology Concept — Clasp will take at least one candidate into the clinic with its new funding • Source: Shutterstock

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.

Key Takeaways

Clasp Therapeutics launched with a $150m series A round to develop off-the-shelf T-cell engagers based on research conducted at Johns Hopkins University.

Cambridge, MA- and Rockville, MD-based Clasp emerged from the labs of cancer genetics specialist Bert Vogelstein and immuno-oncology researcher Drew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abivax Over The Moon As Obefazimod Storms Phase III

23 Jul 2025

• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

22 Jul 2025

• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

22 Jul 2025

• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.